John D Duke bought $25k of HBIO
Chief Executive Officer at HARVARD BIOSCIENCE INC. 5,000 shares at an average of $5.01, traded Mar 16, 2026, filed Mar 17, 2026.
Score components
- +25RoleCEO
- +5Trade size$25k at market
- +3Relative to holdingsHoldings up 5%
- +8Price context37% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.4%, 3m +22.2%, 6m +64.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001171843-26-001645, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | POpen-market purchase Common Stock | +5,000 | $5.01 | $25k | 105,000 | Mar 17, 2026 |
Related signals
Other insiders at HARVARD BIOSCIENCE INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | HARVARD BIOSCIENCE INC | Mark T Frost Chief Financial Officer | $25k 5,000 shares | +40% | |
| 55Moderate | HARVARD BIOSCIENCE INC | Stephen J Denelsky director | $49k 10,000 shares | +91% | |
| 58Moderate | HARVARD BIOSCIENCE INC | William Snider director | $104k 21,000 shares | +191% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.